Genetic Function – Talk Bio

Ansa Biotechnologies Raises $54.4M in Series B to Scale US DNA Synthesis Manufacturing

3 weeks ago talkbio0Tagged Ansa Biotechnologies, Biotechnology, Cerberus Ventures, DNA Replication, Manufacturing, Series B financing, synthetic construct, U.S.

Ansa Biotechnologies; Series B financing; DNA synthesis; Cerberus Ventures; US manufacturing; biotechnology; synthetic DNA; fundraising

Aerska Launches with $21M to Use Brain ‘Shuttles’ for RNAi Delivery in Neurological Diseases

3 weeks ago talkbio0Tagged Aerska, Alzheimer 's, antibody-oligonucleotide, Blood - brain barrier anatomy, brain shuttles, Gene Silencing, Immunostimulating conjugate (antigen), Irish (ethnic group), Neurological diseases, Parkinson 's, Precision Medicine, RNA Interference

Aerska; Irish biotech; RNA interference (RNAi); brain shuttles; blood-brain barrier; neurological diseases; Alzheimer’s; Parkinson’s; gene silencing; precision medicine; antibody-oligonucleotide conjugates

Eli Lilly’s Oral SERD Inluriyo Approved by FDA for ESR1-Mutated Breast Cancer

4 weeks ago talkbio0Tagged Approved, Carcinoma breast stage IV, Eli, Eli Lilly, EMBER-3 trial, ESR1 gene, Estrogen receptor positive, HER2-negative, Imlunestrant, Inluriyo, Mutation, Oral SERD, United States Food and Drug Administration

Eli Lilly; Inluriyo; oral SERD; imlunestrant; FDA approval; ESR1 mutation; metastatic breast cancer; estrogen receptor positive; HER2-negative; EMBER-3 trial

Ono Pharmaceutical and Jorna Therapeutics Announce AI-Driven Research Pact to Develop Novel RNA Editing Medications

1 month ago talkbio0Tagged Artificial Intelligence, Dosage Forms, Japan, Jorna, RNA Editing, SkyEngine

Ono Pharmaceutical; Jorna Therapeutics; RNA editing; AI drug discovery; SkyEngine; biotech partnership; Japan

Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances

2 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Biotechnology, epigenetic therapy, Epigenic, Gene Silencing, Hepatitis B, Hypercholesterolemia, Investments, NRG, Parkinson Disease, Series B funding

Epigenic Therapeutics; NRG Therapeutics; Series B funding; epigenetic therapy; hepatitis B; hypercholesterolemia; Parkinson’s disease; ALS; biotechnology investment; gene silencing

Wave RNA Editing Restores Enzyme in Genetic Disorder but Fails to Impress Investors

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, Clinical Trials, enzyme restoration, Investor Reaction, RNA Editing, Wave Life Sciences, WVE-006

Wave Life Sciences; RNA editing; AATD; alpha-1 antitrypsin deficiency; enzyme restoration; clinical trial; investor reaction; WVE-006

Wave Life Sciences Shares Dip After Mixed Data Update on GSK-Partnered AATD Therapy

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, Clinical Trials, protein levels, RNA Editing, SmithKline Beecham, Wave Life Sciences, WVE-006

Wave Life Sciences; GSK; AATD; RNA editing; WVE-006; clinical trial; protein levels; stock dip; biotech

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

2 months ago talkbio0Tagged ANGPTL3, Biopharma, biotech collaboration, cardiovascular pipeline, Drug Development, Dyslipidemias, milestone payments, Novartis, RNA Interference, RNA, Small Interfering

Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

2 months ago talkbio0Tagged alpha-Synuclein, ARO-SNCA, Arrowhead Pharmaceuticals, biotech partnerships, Gene Silencing, Nerve Degeneration, Novartis, Parkinson 's disease, RNA Interference, TRiM platform

Novartis; Arrowhead Pharmaceuticals; alpha-synuclein; Parkinson’s disease; RNA interference (RNAi); gene silencing; ARO-SNCA; TRiM platform; neurodegeneration; biotech partnerships

Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data

2 months ago talkbio0Tagged Alnylam, Cardiovascular system, Hypertensive disease, KARDIA-3, outcomes, Phase 2 Clinical Trials, Phase 3 Clinical Trials, RNA Interference, Roche (company), ZENITH trial, Zilebesiran

Roche; Alnylam; zilebesiran; hypertension; RNAi therapeutics; KARDIA-3; Phase II trial; Phase III trial; cardiovascular outcomes; ZENITH trial